We are live on ! Find out more
LOGC

LogicBio Therapeutics, Inc. Common Stock
LOGC

Delisted

LOGC was delisted on the 15th of November, 2022.

Back to rankings

40 hedge funds and large institutions have $138M invested in LogicBio Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

18% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 11

8% more funds holding

Funds holding: 37 → 40 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

16% less capital invested

Capital invested by funds: $165M → $138M (-$26.7M)

Holders
40
Holders Change
+3
Holders Change %
+8.11%
% of All Funds
0.88%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
13
Reduced
11
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$839K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$433K
3
Goldman Sachs
Goldman Sachs
New York
+$253K
4
BlackRock
BlackRock
New York
+$165K
5
First Trust Advisors
First Trust Advisors
Illinois
+$154K

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$705K
2
SCM
Sio Capital Management
New York
-$107K
3
Charles Schwab
Charles Schwab
California
-$46.2K
4
Deutsche Bank
Deutsche Bank
Germany
-$44K
5
Northern Trust
Northern Trust
Illinois
-$31.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$69.9M – – –
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$14.9M +$839K +78,475 +6%
BOTOTLSJU
3
Board of Trustees of The Leland Stanford Junior University
California
$10.3M – – –
RG
4
Redmile Group
California
$8.1M -$705K -65,872 -8%
Franklin Resources
5
Franklin Resources
California
$7.57M – – –
SC
6
Samlyn Capital
New York
$6.92M +$15.8K +1,478 +0.2%
LPC
7
Lion Point Capital
New York
$5.41M – – –
BlackRock
8
BlackRock
New York
$5.05M +$165K +15,398 +3%
Vanguard Group
9
Vanguard Group
Pennsylvania
$3.44M +$433K +40,477 +15%
SCM
10
Sio Capital Management
New York
$1.32M -$107K -10,004 -8%
State Street
11
State Street
Massachusetts
$1.29M -$6.97K -652 -0.5%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1M +$8.55K +799 +0.9%
Northern Trust
13
Northern Trust
Illinois
$929K -$31.7K -2,964 -3%
Goldman Sachs
14
Goldman Sachs
New York
$256K +$253K +23,692 New
Bank of New York Mellon
15
Bank of New York Mellon
New York
$225K -$20.2K -1,887 -8%
SLG
16
Stanley-Laman Group
Pennsylvania
$211K – – –
N
17
Nuveen
North Carolina
$202K – – –
Charles Schwab
18
Charles Schwab
California
$197K -$46.2K -4,315 -19%
First Trust Advisors
19
First Trust Advisors
Illinois
$156K +$154K +14,399 New
California State Teachers Retirement System (CalSTRS)
20
California State Teachers Retirement System (CalSTRS)
California
$137K – – –
State of Wisconsin Investment Board
21
State of Wisconsin Investment Board
Wisconsin
$123K – – –
JG
22
Jefferies Group
New York
$115K +$114K +10,618 New
RhumbLine Advisers
23
RhumbLine Advisers
Massachusetts
$108K -$802 -75 -0.7%
Wells Fargo
24
Wells Fargo
California
$107K +$2.71K +253 +3%
UBS Group
25
UBS Group
Switzerland
$69K +$51.8K +4,839 +322%
1
2

LOGC Hedge Fund Activity: Q3 2019 in Review

40 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q3 2019, worth a combined $138M — down 16% from $165M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new LOGC positions and 1 closed out — a net gain of 3 holders — while 13 added to existing stakes and 11 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $839K. The largest seller was Redmile Group, cutting an estimated $705K.

  • 40 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q3 2019, up from 37 in Q2 2019.
  • Funds reported $138M of LogicBio Therapeutics, Inc. Common Stock stock for Q3 2019, down 16% quarter-over-quarter.
  • 4 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q3 2019 and 1 closed out, a net change of +3 holders.
  • The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q3 2019 was Adage Capital Partners, an estimated $839K added.
  • The largest LogicBio Therapeutics, Inc. Common Stock seller in Q3 2019 was Redmile Group, an estimated $705K sold.

Based on aggregated 13F filings for Q3 2019.